CGEM vs RARE · $830.3M cap vs rev $350.0M
Cullinan Oncology LLC (CGEM) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Cullinan Oncology LLC (CGEM) is a biotechnology company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
CGEM does not have a complete income-statement cache yet.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
CGEM currently screens at market cap $830.3M. RARE currently screens at market cap $2.79B.
Not investment advice. Open the CGEM and RARE stock pages for the full models.
Not investment advice.